Why You Should Add Encompass Health (EHC) to Your Portfolio Now

Zacks05-17

Encompass Health Corporation EHC is aided by growing patient volumes, a sound business outlook for 2024, an expanding healthcare portfolio and a notable financial position. Top Zacks Rank & Upbeat ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2436985594?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cQh8dmZYcaVCEef9kDcJiQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e1e661692a97423f623854b9b5e54b7d","is_english":true,"pubTime":"2024-05-17 00:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2436985594","market":"us","top_or_hot":-1,"title":"Why You Should Add Encompass Health (EHC) to Your Portfolio Now","media":"Zacks","content":"<div>\n<p>Encompass Health Corporation EHC is aided by growing patient volumes, a sound business outlook for 2024, an expanding healthcare portfolio and a notable financial position.\nTop Zacks Rank & Upbeat ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-add-encompass-health-ehc-164500597.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why You Should Add Encompass Health (EHC) to Your Portfolio Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy You Should Add Encompass Health (EHC) to Your Portfolio Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-17 00:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-add-encompass-health-ehc-164500597.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Encompass Health Corporation EHC is aided by growing patient volumes, a sound business outlook for 2024, an expanding healthcare portfolio and a notable financial position.\nTop Zacks Rank & Upbeat ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-add-encompass-health-ehc-164500597.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/why-add-encompass-health-ehc-164500597.html","article_id":"2436985594","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cQh8dmZYcaVCEef9kDcJiQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e1e661692a97423f623854b9b5e54b7d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2436985594","pubTimestamp":1715877900,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Encompass Health Corporation EHC is aided by growing patient volumes, a sound business outlook for 2024, an expanding healthcare portfolio and a notable financial position.Encompass Health currently carries a Zacks Rank #2 .The EHC stock has gained 43.1% in the past year compared with the industry’s 24.3% growth. The Zacks Medical sector has rallied 4.6% and the S&P 500 composite has risen 27.6% in the same time frame.The Zacks Consensus Estimate for Encompass Health’s 2024 earnings is pegged at $4.09 per share, suggesting growth of 12.4% from the prior-year reported figure. The consensus mark for 2025 earnings is pegged at $4.56 per share, indicating an improvement of 11.5% from the 2024 estimate.The expected long-term earnings growth rate is pegged at 15.6%, better than the industry’s average of 12%.The Inpatient Rehabilitation unit holds growth potential owing to the active expansion endeavor that it usually resorts to throughout the year. Encompass Health either takes sole responsi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc.","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4007":"制药","EHC":"Encompass Health Corporation","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4082":"医疗保健设备","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4185":"保健护理机构","OGN":"Organon & Co","BK4139":"生物科技","BK4588":"碎股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LMAT":"勒梅特微管医疗"},"translate_title":"为什么您现在应该将Encompass Health（EHC）添加到您的投资组合中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":1,"EHC":1,"LGND":1,"LMAT":1},"content_text":"Encompass Health Corporation EHC is aided by growing patient volumes, a sound business outlook for 2024, an expanding healthcare portfolio and a notable financial position.\nTop Zacks Rank & Upbeat Price Performance\nEncompass Health currently carries a Zacks Rank #2 (Buy).\nThe EHC stock has gained 43.1% in the past year compared with the industry’s 24.3% growth. The Zacks Medical sector has rallied 4.6% and the S&P 500 composite has risen 27.6% in the same time frame.\nImage Source: Zacks Investment Research\n \nFavorable Style Score\nEHC carries an impressive Value Score of A. Value Score helps find stocks that are undervalued. Back-tested results have shown so far that stocks with a favorable Value Score in combination with a solid Zacks Rank are the best investment bets.\nRobust Growth Prospects\nThe Zacks Consensus Estimate for Encompass Health’s 2024 earnings is pegged at $4.09 per share, suggesting growth of 12.4% from the prior-year reported figure. The consensus mark for 2025 earnings is pegged at $4.56 per share, indicating an improvement of 11.5% from the 2024 estimate.The expected long-term earnings growth rate is pegged at 15.6%, better than the industry’s average of 12%.\nNorthbound Estimate Revision\nThe Zacks Consensus Estimate for 2024 earnings has been revised upward 3.3% in the past 30 days.\nImpressive Earnings Surprise History\nEHC’s bottom line outpaced estimates in each of the trailing four quarters, the average surprise being 18.74%.\nValuation: Cheaply Priced\nPrice-to-earnings (P/E) is one of the multiples used for valuing healthcare stocks.  Encompass Health has a reading of 20.43 compared with the industry’s forward 12-month P/E ratio of 21.39. It is quite evident that the stock is currently undervalued.\nA Strong View for 2024\nEHC forecasts revenues within the range of $5.25-$5.325 billion for 2024, the midpoint of which indicates an improvement of 10.1% from the 2023 reported figure.  \nAdjusted earnings per share from continuing operations are anticipated between $3.86 and $4.11, the midpoint of which suggests 9.5% growth from the 2023 level.\nKey Business Tailwinds\nThe top line of Encompass Health is aided by a growing patient base at its inpatient rehabilitation hospitals. Its revenues rose 13.4% year over year in the first quarter. The dire need for specialized rehabilitative treatment that helps people recovering from chronic illnesses and injuries return to normal daily activities is likely to sustain the solid demand for services provided by its Inpatient Rehabilitation segment.\nThe Inpatient Rehabilitation unit holds growth potential owing to the active expansion endeavor that it usually resorts to throughout the year. Encompass Health either takes sole responsibility or forms joint ventures with renowned healthcare organizations to build inpatient rehabilitation hospitals across different U.S. communities and make the same operable within a reasonable time frame. Each hospital inauguration advances the capabilities and expands the nationwide foothold of Encompass Health.\nCurrently, it operates 161 hospitals across 37 states and Puerto Rico.  The company expects to open six de novo hospitals in 2024. It also expects to add around 150 beds to existing hospitals this year. Over the 2023-2027 period, management aims to inaugurate six to ten de novos and make bed additions in the range of 80-120 each year.\nA strong financial position provides a cushion for Encompass Health to pursue such uninterrupted growth-related initiatives. A growing cash reserve and solid cash-generating abilities bear testament to the same. As of Mar 31, 2024, cash and cash equivalents surged 94.5% from the 2023-end level. It also generated operating cash flows of $238.8 million in the first quarter, which improved 4.8% year over year.  Adjusted free cash flow is anticipated to lie between $475 million and $570 million for 2024.\nOther Stocks to Consider\nSome other top-ranked stocks in the Medical space are Ligand Pharmaceuticals Incorporated LGND, Organon & Co. OGN and LeMaitre Vascular, Inc. LMAT, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nLigand Pharmaceuticals’ earnings surpassed estimates in each of the last four quarters, the average surprise being 56.02%. The Zacks Consensus Estimate for LGND’s 2024 earnings indicates a rise of 12.3% while the consensus mark for revenues suggests an improvement of 6% from the respective year-ago actuals. The consensus mark for LGND’s 2024 earnings has moved 3.2% north in the past 60 days.\nOrganon’s earnings beat estimates in three of the trailing four quarters and missed the mark once, the average surprise being 13.62%. The Zacks Consensus Estimate for OGN’s 2024 earnings indicates a rise of 6.8% while the consensus mark for revenues suggests an improvement of 1.7% from the respective year-ago actuals. The consensus mark for OGN’s 2024 earnings has moved 4.7% north in the past 30 days.\nThe bottom line of LeMaitre Vascular outpaced estimates in each of the trailing four quarters, the average surprise being 10.12%. The Zacks Consensus Estimate for LMAT’s 2024 earnings indicates a rise of 28.2% while the consensus mark for revenues suggests an improvement of 11.3% from the respective year-ago actuals. The consensus mark for LMAT’s 2024 earnings has moved 5.5% north in the past 30 days.Shares of Ligand Pharmaceuticals, Organon and LeMaitre Vascular have gained 9.1%, 3.8% and 21.9%, respectively, in the past year.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nLeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report\nEncompass Health Corporation (EHC) : Free Stock Analysis Report\nOrganon & Co. (OGN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436985594"}